A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus α1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia
Jung, K.; Brux, B.; Knabich, A.; Lein, M.; Sinha, P.; Schnorr, D.; Loening, S.A.
Clinical Chemistry (Baltimore, Md.) 45(3): 422-424
1999
ISSN/ISBN: 0009-9147 Accession: 073670148
PDF emailed within 1 workday: $29.90
Related References
Jung, K.; Brux, B.; Knäbich, A.; Lein, M.; Sinha, P.; Schnorr, D.; Loening, S.A. 1999: A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia Clinical Chemistry 45(3): 422-424Auprich, M.; Augustin, H.; Budäus, L.; Kluth, L.; Mannweiler, S.; Shariat, S.F.; Fisch, M.; Graefen, M.; Pummer, K.; Chun, F.K.-H. 2012: A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy Bju International 109(11): 1627-1635
Morote, J.; Raventós, C.X.; Lorente, J.A.; Lopez-Pacios, M.A.; Encabo, G.; de Torres, I.; Andreu, J. 1997: Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml Journal of Urology 158(2): 502-504
Lein, M.; Jung, K.; Elgeti, U.; Petras, T.; Stephan, C.; Brux, B.; Sinha, P.; Winkelmann, B.; Schnorr, D.; Loening, S. 2001: Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis European Urology 39(1): 57-64
Stephan, C.; Lein, M.; Jung, K.; Schnorr, D.; Loening, S.A. 1997: The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia Cancer 79(1): 104-109
Yamamoto, S.; Maruyama, T.; Kondoh, N.; Nojima, M.; Takiuchi, H.; Hirota, S.; Shima, H. 2008: Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml International Urology and Nephrology 40(1): 85-89
Caliskan, S. 2017: Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml) Journal of Cancer Research and Therapeutics 13(2): 279-283
Catalona, W.J.; Partin, A.W.; Sanda, M.G.; Wei, J.T.; Klee, G.G.; Bangma, C.H.; Slawin, K.M.; Marks, L.S.; Loeb, S.; Broyles, D.L.; Shin, S.S.; Cruz, A.B.; Chan, D.W.; Sokoll, L.J.; Roberts, W.L.; van Schaik, R.H.N.; Mizrahi, I.A. 2011: A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range Journal of Urology 185(5): 1650-1655
Le, B.V.; Griffin, C.R.; Loeb, S.; Carvalhal, G.F.; Kan, D.; Baumann, N.A.; Catalona, W.J. 2010: -2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study Journal of Urology 183(4): 1355-1359
Ellis, W.J.; Etzioni, R.; Vessella, R.L.; Hu, C.; Goodman, G.E. 2001: Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer Journal of Urology 166(1): 93
Crook, J.M.; Bahadur, Y.A.; Bociek, R.G.; Perry, G.A.; Robertson, S.J.; Esche, B.A. 1997: Radiotherapy for localized prostate carcinoma : The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen Canadian Urologic Association Meeting 79(2): 328-336
Crook, J.M.; Bahadur, Y.A.; Bociek, R.G.; Perry, G.A.; Robertson, S.J.; Esche, B.A. 1997: Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen Cancer 79(2): 328-336
Garrido, M.M.; Marta, J.é C.; Bernardino, R.M.; Guerra, J.ão.; Fernandes, F.; Pereira, M.H.; Ribeiro, R.; Holdenrieder, S.; Pinheiro, L.ís.C.; Guimarães, J.ão.T. 2022: The Percentage of [-2]Pro-Prostate-Specific Antigen and the Prostate Health Index Outperform Prostate-Specific Antigen and the Percentage of Free Prostate-Specific Antigen in the Detection of Clinically Significant Prostate Cancer and can be Used as Reflex Tests Archives of Pathology and Laboratory Medicine 146(6): 691-700
Ornstein, D.K.; Smith, D.S.; Humphrey, P.A.; Catalona, W.J. 1998: The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer Journal of Urology 159(4): 1234-1237
Fujinami, K.; Miura, T.; Takizawa, A.; Osada, Y.; Kawakami, S. 2005: Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1-10 ng/ml Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 96(4): 475-479
Işikay, L.; Yaman O; Bozlu, M.; Müftüğlu, Y.Z.; Göğüş, O. 1995: Prostate-specific antigen density: The role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma International Urology and Nephrology 27(6): 757-761
Choi, H.; Park, J.Y.; Shim, J.S.; Kim, J.H.; Bae, J.H. 2013: Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population International Neurourology Journal 17(2): 73-77
Chiang, I.-N.; Chang, S.-J.; Pu, Y.-S.; Huang, K.-H.; Yu, H.-J.; Huang, C.-Y. 2009: Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection Urologia Internationalis 82(3): 270-275
Damu, Y.A.N.G.; Holt, G.E.; Velders, M.P.; Kwon, E.D.; Kast, W.M. 2001: Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen : Prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice Cancer Research (Baltimore) 61(15): 5857-5860
Yang, D.; Holt, G.E.; Velders, M.P.; Kwon, E.D.; Kast, W.M. 2001: Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice Cancer Research 61(15): 5857-5860